Golimumab (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Golimumab" in Italian language version.

refsWebsite

Global rank Italian rank

10nih.gov

4^th place

9^th place

9doi.org

2^nd place

7^th place

8oadoi.org

799^th place

22^nd place

2wikiwix.com

194^th place

345^th place

1europa.eu

68^th place

57^th place

1landesbioscience.com

low place

1archive.org

6^th place

8^th place

archive.org

JS. Smolen, J. Kay; RB. Landewé; EL. Matteson; N. Gaylis; J. Wollenhaupt; FT. Murphy; Y. Zhou; EC. Hsia; MK. Doyle, Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160., in Ann Rheum Dis, vol. 71, n. 10, ottobre 2012, pp. 1671-9, DOI:10.1136/annrheumdis-2011-200956, PMID 22459542.

doi.org

dx.doi.org

Z. Xu, Q. Wang; Y. Zhuang; B. Frederick; H. Yan; E. Bouman-Thio; JC. Marini; M. Keen; D. Snead; HM. Davis; H. Zhou, Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects., in J Clin Pharmacol, vol. 50, n. 3, marzo 2010, pp. 276-84, DOI:10.1177/0091270009340782, PMID 19940229.
H. Zhou, H. Jang; RM. Fleischmann; E. Bouman-Thio; Z. Xu; JC. Marini; C. Pendley; Q. Jiao; G. Shankar; SJ. Marciniak; SB. Cohen, Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis., in J Clin Pharmacol, vol. 47, n. 3, marzo 2007, pp. 383-96, DOI:10.1177/0091270006298188, PMID 17322150.
Y. Zhuang, Z. Xu; B. Frederick; DE. de Vries; JA. Ford; M. Keen; MK. Doyle; KJ. Petty; HM. Davis; H. Zhou, Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study., in Clin Ther, vol. 34, n. 1, gennaio 2012, pp. 77-90, DOI:10.1016/j.clinthera.2011.11.015, PMID 22169051.
P. Emery, R. Fleischmann; D. van der Heijde; EC. Keystone; MC. Genovese; PG. Conaghan; EC. Hsia; W. Xu; A. Baratelle; A. Beutler; MU. Rahman, The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy., in Arthritis Rheum, vol. 63, n. 5, maggio 2011, pp. 1200-10, DOI:10.1002/art.30263, PMID 21305524.
EC. Keystone, MC. Genovese; L. Klareskog; EC. Hsia; ST. Hall; PC. Miranda; J. Pazdur; SC. Bae; W. Palmer; J. Zrubek; M. Wiekowski, Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study., in Ann Rheum Dis, vol. 68, n. 6, giugno 2009, pp. 789-96, DOI:10.1136/ard.2008.099010, PMID 19066176.
E. Keystone, MC. Genovese; L. Klareskog; EC. Hsia; S. Hall; PC. Miranda; J. Pazdur; SC. Bae; W. Palmer; S. Xu; MU. Rahman, Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study., in Ann Rheum Dis, vol. 69, n. 6, giugno 2010, pp. 1129-35, DOI:10.1136/ard.2009.116319, PMID 20444749.
MC. Genovese, C. Han; EC. Keystone; EC. Hsia; J. Buchanan; T. Gathany; FT. Murphy; Z. Wu; S. Parasuraman; MU. Rahman, Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study., in J Rheumatol, vol. 39, n. 6, giugno 2012, pp. 1185-91, DOI:10.3899/jrheum.111195, PMID 22505702.
JS. Smolen, J. Kay; MK. Doyle; R. Landewé; EL. Matteson; J. Wollenhaupt; N. Gaylis; FT. Murphy; JS. Neal; Y. Zhou; S. Visvanathan, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial., in Lancet, vol. 374, n. 9685, luglio 2009, pp. 210-21, DOI:10.1016/S0140-6736(09)60506-7, PMID 19560810.
JS. Smolen, J. Kay; RB. Landewé; EL. Matteson; N. Gaylis; J. Wollenhaupt; FT. Murphy; Y. Zhou; EC. Hsia; MK. Doyle, Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160., in Ann Rheum Dis, vol. 71, n. 10, ottobre 2012, pp. 1671-9, DOI:10.1136/annrheumdis-2011-200956, PMID 22459542.

europa.eu

ema.europa.eu

EMEA, European Medicines Agency - Simponi, su ema.europa.eu. URL consultato il 16 febbraio 2013.

landesbioscience.com

(EN) Landes Bioscience Journals: mAbs, su landesbioscience.com.

nih.gov

ncbi.nlm.nih.gov

Z. Xu, Q. Wang; Y. Zhuang; B. Frederick; H. Yan; E. Bouman-Thio; JC. Marini; M. Keen; D. Snead; HM. Davis; H. Zhou, Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects., in J Clin Pharmacol, vol. 50, n. 3, marzo 2010, pp. 276-84, DOI:10.1177/0091270009340782, PMID 19940229.
H. Zhou, H. Jang; RM. Fleischmann; E. Bouman-Thio; Z. Xu; JC. Marini; C. Pendley; Q. Jiao; G. Shankar; SJ. Marciniak; SB. Cohen, Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis., in J Clin Pharmacol, vol. 47, n. 3, marzo 2007, pp. 383-96, DOI:10.1177/0091270006298188, PMID 17322150.
Y. Zhuang, Z. Xu; B. Frederick; DE. de Vries; JA. Ford; M. Keen; MK. Doyle; KJ. Petty; HM. Davis; H. Zhou, Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study., in Clin Ther, vol. 34, n. 1, gennaio 2012, pp. 77-90, DOI:10.1016/j.clinthera.2011.11.015, PMID 22169051.
V. Oldfield, GL. Plosker, Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis., in BioDrugs, vol. 23, n. 2, 2009, pp. 125-35, PMID 19489653.
P. Emery, R. Fleischmann; D. van der Heijde; EC. Keystone; MC. Genovese; PG. Conaghan; EC. Hsia; W. Xu; A. Baratelle; A. Beutler; MU. Rahman, The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy., in Arthritis Rheum, vol. 63, n. 5, maggio 2011, pp. 1200-10, DOI:10.1002/art.30263, PMID 21305524.
EC. Keystone, MC. Genovese; L. Klareskog; EC. Hsia; ST. Hall; PC. Miranda; J. Pazdur; SC. Bae; W. Palmer; J. Zrubek; M. Wiekowski, Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study., in Ann Rheum Dis, vol. 68, n. 6, giugno 2009, pp. 789-96, DOI:10.1136/ard.2008.099010, PMID 19066176.
E. Keystone, MC. Genovese; L. Klareskog; EC. Hsia; S. Hall; PC. Miranda; J. Pazdur; SC. Bae; W. Palmer; S. Xu; MU. Rahman, Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study., in Ann Rheum Dis, vol. 69, n. 6, giugno 2010, pp. 1129-35, DOI:10.1136/ard.2009.116319, PMID 20444749.
MC. Genovese, C. Han; EC. Keystone; EC. Hsia; J. Buchanan; T. Gathany; FT. Murphy; Z. Wu; S. Parasuraman; MU. Rahman, Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study., in J Rheumatol, vol. 39, n. 6, giugno 2012, pp. 1185-91, DOI:10.3899/jrheum.111195, PMID 22505702.
JS. Smolen, J. Kay; MK. Doyle; R. Landewé; EL. Matteson; J. Wollenhaupt; N. Gaylis; FT. Murphy; JS. Neal; Y. Zhou; S. Visvanathan, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial., in Lancet, vol. 374, n. 9685, luglio 2009, pp. 210-21, DOI:10.1016/S0140-6736(09)60506-7, PMID 19560810.
JS. Smolen, J. Kay; RB. Landewé; EL. Matteson; N. Gaylis; J. Wollenhaupt; FT. Murphy; Y. Zhou; EC. Hsia; MK. Doyle, Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160., in Ann Rheum Dis, vol. 71, n. 10, ottobre 2012, pp. 1671-9, DOI:10.1136/annrheumdis-2011-200956, PMID 22459542.

oadoi.org

Z. Xu, Q. Wang; Y. Zhuang; B. Frederick; H. Yan; E. Bouman-Thio; JC. Marini; M. Keen; D. Snead; HM. Davis; H. Zhou, Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects., in J Clin Pharmacol, vol. 50, n. 3, marzo 2010, pp. 276-84, DOI:10.1177/0091270009340782, PMID 19940229.
H. Zhou, H. Jang; RM. Fleischmann; E. Bouman-Thio; Z. Xu; JC. Marini; C. Pendley; Q. Jiao; G. Shankar; SJ. Marciniak; SB. Cohen, Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis., in J Clin Pharmacol, vol. 47, n. 3, marzo 2007, pp. 383-96, DOI:10.1177/0091270006298188, PMID 17322150.
Y. Zhuang, Z. Xu; B. Frederick; DE. de Vries; JA. Ford; M. Keen; MK. Doyle; KJ. Petty; HM. Davis; H. Zhou, Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study., in Clin Ther, vol. 34, n. 1, gennaio 2012, pp. 77-90, DOI:10.1016/j.clinthera.2011.11.015, PMID 22169051.
P. Emery, R. Fleischmann; D. van der Heijde; EC. Keystone; MC. Genovese; PG. Conaghan; EC. Hsia; W. Xu; A. Baratelle; A. Beutler; MU. Rahman, The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy., in Arthritis Rheum, vol. 63, n. 5, maggio 2011, pp. 1200-10, DOI:10.1002/art.30263, PMID 21305524.
EC. Keystone, MC. Genovese; L. Klareskog; EC. Hsia; ST. Hall; PC. Miranda; J. Pazdur; SC. Bae; W. Palmer; J. Zrubek; M. Wiekowski, Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study., in Ann Rheum Dis, vol. 68, n. 6, giugno 2009, pp. 789-96, DOI:10.1136/ard.2008.099010, PMID 19066176.
E. Keystone, MC. Genovese; L. Klareskog; EC. Hsia; S. Hall; PC. Miranda; J. Pazdur; SC. Bae; W. Palmer; S. Xu; MU. Rahman, Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study., in Ann Rheum Dis, vol. 69, n. 6, giugno 2010, pp. 1129-35, DOI:10.1136/ard.2009.116319, PMID 20444749.
MC. Genovese, C. Han; EC. Keystone; EC. Hsia; J. Buchanan; T. Gathany; FT. Murphy; Z. Wu; S. Parasuraman; MU. Rahman, Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study., in J Rheumatol, vol. 39, n. 6, giugno 2012, pp. 1185-91, DOI:10.3899/jrheum.111195, PMID 22505702.
JS. Smolen, J. Kay; MK. Doyle; R. Landewé; EL. Matteson; J. Wollenhaupt; N. Gaylis; FT. Murphy; JS. Neal; Y. Zhou; S. Visvanathan, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial., in Lancet, vol. 374, n. 9685, luglio 2009, pp. 210-21, DOI:10.1016/S0140-6736(09)60506-7, PMID 19560810.

wikiwix.com

archive.wikiwix.com

(EN) adisonline.com (archiviato dall'url originale il 1º luglio 2011).
(EN) adisonline.com (archiviato dall'url originale il 1º luglio 2011).